至 2028 年亚太地区品牌仿制药市场预测 – COVID-19 影响和区域分析 – 按治疗应用(肿瘤学、心血管疾病、糖尿病、神经病学、胃肠道疾病、皮肤病、镇痛药和抗炎药等),分销渠道(医院、零售药店、网上药店和药店)、药品类别(烷化剂、抗代谢药、激素、抗高血压药、降脂药、抗抑郁药、抗精神病药、抗癫痫药等)和制剂类型(口服、肠外注射) 、专题和其他)

Historic Data: 2020-2021   |   Base Year: 2022   |   Forecast Period: 2023-2028


No. of Pages: 185    |    Report Code: BMIRE00026044    |    Category: Life Sciences

Asia Pacific Branded Generics Market

亚太地区的品牌仿制药市场预计将从2022年的714.5亿美元增长到2028年的1303.9亿美元;预计 2022 年至 2028 年复合年增长率为 10.5%。

 

在线科学电子图书馆 (SciELO) )报告指出,推广品牌仿制药是各国国家医药政策的核心工具,最终通过扩大医疗服务范围来减少药品支出。 2008年11月,化工部医药司肥料方面,印度政府推出了 Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP),以实惠的价格提供优质仿制药。根据该计划,名为 Janaushadhi Kendras 的专门销售点以实惠的价格提供仿制药。截至 2021 年,全国有 8,012 个 Janaushadhi Kendras 在运作。此外,美国食品和药物管理局 (FDA) 的一份报告指出,如果 FDA 批准大多数品牌仿制药,它可以降低药品成本。一般来说,同一产品的多种仿制药会造成市场竞争。例如,单一仿制药竞争对手导致价格下降高达 30%,而五个竞争仿制药则导致价格下降近 85%。

世界卫生组织估计,尽管印度是最大的仿制药制造商和供应商之一,但约 65% 的印度人口无法定期获得基本药物。政府批量采购仿制药的价格低于个人消费者购买品牌药的价格。它可以降低至品牌药零售价的 2%。因此,与免费药品相关的规定是减轻医疗费用负担的最重要的干预措施之一。印度政府提出的可持续发展目标的目标之一是实现全民医疗保健覆盖,包括金融风险保障;获得优质基本医疗保健服务;以及获得安全、有效、优质和负担得起的基本药物。因此,政府推广品牌仿制药举措的兴起推动了亚太地区品牌仿制药市场的增长。

 

通过引入新功能和技术,亚太品牌仿制药市场的供应商可以吸引新客户并扩大其在新兴市场的足迹。这一因素可能会在预测期内推动市场实现良好的复合年增长率。

 

 亚太地区品牌仿制药< /strong>

到 2028 年的市场收入和预测(十亿美元)

< /span>

 

 

 

亚太地区品牌仿制药市场细分 < /strong>

 

亚太地区品牌仿制药市场分为治疗应用、分销渠道、药物类别、制剂类型和国家。亚太品牌仿制药市场的治疗应用细分为肿瘤、心血管疾病、糖尿病、神经病学、胃肠道疾病、皮肤病、镇痛抗炎。 2022 年,按治疗应用划分,其他细分市场占据最大市场份额。亚太地区品牌仿制药市场按分销渠道划分为医院药房、零售药房、网上药房和药店。到 2022 年,零售药房市场可能会占据最大的市场份额。亚太地区品牌仿制药市场按药物类别分为烷化剂、抗代谢药物、激素、抗高血压、降脂药物、抗抑郁药物、 - 精神病药、抗癫痫药等。其他细分市场可能会在 2022 年占据最大的市场份额。亚太地区品牌仿制药市场根据剂型类型分为口服、肠胃外、外用和其他。 2022 年,按配方类型划分,口服细分市场占据最大市场份额。根据国家/地区,亚太地区品牌仿制药市场分为澳大利亚、中国、印度、日本、韩国和亚太地区其他地区。 2022 年,中国占据最大市场份额。

 

阿斯彭控股、阿斯利康、Bausch Health(Valeant Pharmaceuticals)、Dr. Reddy\'s Laboratories Inc. 、葛兰素史克公司、Hetero、Lupin、Mylan NV、Par Pharmaceuticals、Sandoz International Gmbh、赛诺菲和 Teva Pharmaceutical Industries Ltd. 是该地区品牌仿制药市场的领先公司。  



Asia Pacific Branded Generics Strategic Insights

Strategic insights for Asia Pacific Branded Generics involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.

strategic-framework/asia-pacific-branded-generics-market-strategic-framework.webp
Get more information on this report

Asia Pacific Branded Generics Report Scope

Report Attribute Details
Market size in 2022 US$ 71.45 Billion
Market Size by 2028 US$ 130.39 Billion
Global CAGR (2022 - 2028) 10.5%
Historical Data 2020-2021
Forecast period 2023-2028
Segments Covered By 治疗应用
  • 肿瘤科
  • 心血管疾病
  • 糖尿病
  • 神经内科
  • 胃肠道疾病
  • 皮肤病
  • 镇痛消炎
By 分销渠道
  • 医院
  • 零售药店
  • 网上药店
  • 药店
By 药物类别
  • 烷化剂
  • 抗代谢药
  • 激素
  • 抗高血压药
  • 降脂药
  • 抗抑郁药
  • 抗精神病药
  • 抗癫痫药
By 剂型类型
  • 口服
  • 肠胃外
  • 外用
Regions and Countries Covered 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳大利亚
  • 亚太其他地区
Market leaders and key company profiles
  • Aspen Holdings
  • AstraZeneca
  • Bausch Health (Valeant Pharmaceuticals)
  • Dr. Reddys Laboratories Inc.
  • GlaxoSmithKline plc
  • Hetero
  • Lupin
  • Mylan N.V.
  • Par Pharmaceuticals
  • Sandoz International Gmbh
  • Get more information on this report

    Asia Pacific Branded Generics Regional Insights

    The regional scope of Asia Pacific Branded Generics refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.

    geography/asia-pacific-branded-generics-market-geography.webp
    Get more information on this report

    The List of Companies - Asia Pacific Branded Generics Market

    1. Aspen Holdings
    2. AstraZeneca
    3. Bausch Health (Valeant Pharmaceuticals)
    4. Dr. Reddy's Laboratories Inc.
    5. GlaxoSmithKline plc
    6. Hetero
    7. Lupin
    8. Mylan N.V.
    9. Par Pharmaceuticals
    10. Sandoz International Gmbh
    11. Sanofi
    12. Teva Pharmaceutical Industries Ltd.
    Frequently Asked Questions
    How big is the Asia Pacific Branded Generics Market?

    The Asia Pacific Branded Generics Market is valued at US$ 71.45 Billion in 2022, it is projected to reach US$ 130.39 Billion by 2028.

    What is the CAGR for Asia Pacific Branded Generics Market by (2022 - 2028)?

    As per our report Asia Pacific Branded Generics Market, the market size is valued at US$ 71.45 Billion in 2022, projecting it to reach US$ 130.39 Billion by 2028. This translates to a CAGR of approximately 10.5% during the forecast period.

    What segments are covered in this report?

    The Asia Pacific Branded Generics Market report typically cover these key segments-

  • 治疗应用 (肿瘤科, 心血管疾病, 糖尿病, 神经内科, 胃肠道疾病, 皮肤病, 镇痛消炎)
  • 分销渠道 (医院, 零售药店, 网上药店, 药店)
  • 药物类别 (烷化剂, 抗代谢药, 激素, 抗高血压药, 降脂药, 抗抑郁药, 抗精神病药, 抗癫痫药)
  • What is the historic period, base year, and forecast period taken for Asia Pacific Branded Generics Market?

    The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Branded Generics Market report:

  • Historic Period : 2020-2021
  • Base Year : 2022
  • Forecast Period : 2023-2028
  • Who are the major players in Asia Pacific Branded Generics Market?

    The Asia Pacific Branded Generics Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • Aspen Holdings
  • AstraZeneca
  • Bausch Health (Valeant Pharmaceuticals)
  • Dr. Reddys Laboratories Inc.
  • GlaxoSmithKline plc
  • Hetero
  • Lupin
  • Mylan N.V.
  • Par Pharmaceuticals
  • Sandoz International Gmbh
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • Who should buy this report?

    The Asia Pacific Branded Generics Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the Asia Pacific Branded Generics Market value chain can benefit from the information contained in a comprehensive market report.